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The impact of antigen density and antibody affinity on
antibody-dependent cellular cytotoxicity: relevance for
immunotherapy of carcinomas
MP Velders*, CM van Rhijn, E Oskam, GJ Fleuren, SO Warnaar and SV Litvinov
Department of Pathology, Leiden University, University Hospital Building 1, Li -Q, PO Box 9600, 2300 RC Leiden, The Netherlands
Summary Antibody-dependent cellular cytotoxicity (ADCC) is considered to be the major mechanism through which tumour cells, upon
treatment with anti-tumour MAbs, are eliminated in vivo. However, the relative importance of various parameters that influence the efficacy of
ADCC is unclear. Here we present in vitro data on the impact of MAb affinity and antigen density on ADCC, as obtained by comparison of two
MAbs against the tumour-associated antigen Ep-CAM. The low-affinity MAb 17-1A (Ka = 5 x 107 M-1) currently used fortherapy, and the high-
affinity MAb 323/A3 (Ka = 2 x 109 M-1), were compared in ADCC experiments against murine and human tumour target cells transfected with
the Ep-CAM cDNA under the control of an inducible promoter to enable regulation of the target antigen expression levels. Data obtained from
these studies revealed that the high-affinity MAb, in contrast to the low-affinity MAb, could mediate killing of tumour cells with low antigen
expression levels. Even at comparable MAb-binding levels, ADCC mediated by the high-affinity MAb was more effective. The kinetics of
ADCC was also found to be determined by the level of antigen expression, and by the affinity and the concentration of the MAb used. The
efficacy of ADCC with both low- and high-affinity MAbs further depended on adhesive interactions between effector and target cells mediated
by CD18. However, at every given MAb concentration these interactions were of less importance for the high-affinity MAb than for the low-
affinity MAb. As heterogeneity of a target antigen expression is a common feature of all tumours, and some tumour cells express very low
levels of the antigen, the use of high-affinity MAbs in immunotherapy may significantly improve the clinical results obtained to the present date
in the treatment of minimal residual disease.
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A wide range of monoclonal antibodies (MAbs) against tumour-
associated antigens is available to combat various forms of
human neoplasia. Application of such unconjugated MAbs in an
immunotherapeutic setting can only be effective ifall tumour cells
express the targeted antigen in amounts that allow sufficient
binding of MAb to trigger the effector mechanisms that eliminate
the tumour cells (Herlyn et al, 1985). When patients with minimal
residual disease, after surgery of Dukes' C colon carcinoma, were
treated with MAb 17-lA, a reduction in the 5-year mortality of
30% was observed compared with a control group (Riethmuller et
al, 1994). Although the increase in the 5-year survival obtained in
this trial is clinically very important, the results might be improved
with a better understanding ofthe parameters that play a role in the
antibody-mediated interactions between the target cell and the
effector mechanisms.
Antibody-mediated effector mechanisms against tumour cells, of
which the activity has been shown in vitro, are antibody-dependent
cellular cytotoxicity (ADCC) (Steplewski et al, 1988; Herlyn and
Koprowski, 1982) and complement-mediated cytotoxicity (Orlandi
et al, 1992; Velders et al, 1994). The presence in tumours, surgically
removed from MAb-treated patients, of infiltrating natural killer
cells and of macrophages (Adams et al, 1984; Shetye et al, 1988) as
well as of complement deposits (Adams et al, 1984), suggests that
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both ADCC and complement-mediated cytotoxicity may play a role
in tumour cell destruction in vivo. However, as most tumour cells
express increased amounts of complement-inhibiting regulators
which protect the cells against lysis by autologous complement
(Kumar et al, 1993; Gorter et al, 1996), the main anti-tumour mech-
anism of therapeutic antibodies in vivo is considered to be ADCC.
The impact of antigen density and antibody affinity on the efficacy
of tumour cell elimination via ADCC is relatively poorly studied,
mainly because ofthe lack ofadequate models.
In the clinical trial mentioned above (Riethmuller et al, 1994),
the epithelial cell adhesion molecule (Ep-CAM) (Litvinov et al,
1994 a,b; 1995), a human 40-kDa epithelial glycoprotein, and one
of the most frequently targeted tumour-associated antigens, was
the target antigen for the murine MAb 17-1A. This MAb has been
recently approved in Germany as a therapeutic reagent for the treat-
ment of Dukes' C colorectal cancer; this indicates that Ep-CAM as
a target antigen has a future in immunotherapy. Therefore, in the
present study on factors defining the efficacy of ADCC, we have
chosen Ep-CAM as the target antigen. Ep-CAM was targeted by
MAbs 17-lA and 323/A3, which recognize overlapping epitopes
on the Ep-CAM molecule and compete for binding to EP-CAM.
The 323/A3 MAb affinity for Ep-CAM was found to be 40-fold
higher than the affinity of MAb 17-lA (Pak et al, 1991; Velders
et al, 1994; 1996). To obtain model cell lines, in which the surface
expression of Ep-CAM could be varied, the Ep-CAM cDNA was
introduced into Ep-CAM-negative murine and human cell lines
under the transcriptional control of an inducible promoter.
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The results of this study demonstrate that the efficacy and
kinetics of ADCC are determined by both antibody affinity and
antigen density. In addition, ADCC was shown to be dependent on
LFA-I-mediated interactions, however the high-affinity MAb
323/A3 was to a lesser extent dependent on these interactions than
the low-affinity MAb 17-1A.
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MATERIALS AND METHODS
Antibodies
For all in vitro experiments with human effector cells the chimeric
human/mouse versions of the antibodies 17-1A and 323/A3 were
used (Sun et al, 1987; Velders et al, 1994). The chimeric antibodies
contain the same human IgG1 and kappa-constant domains as both
MAbs were chimerized at Centocor using identical methods and
vectors. All antibodies were initially purified over protein A-
Sepharose (Pharmacia, Woerden, The Netherlands), and were
further purified by sequential ion-exchange chromatography on
Mono S and Mono Q (Pharmacia) columns, followed by diafiltra-
tion into phosphate-buffered saline (PBS). All antibody prepara-
tions were tested using LAL assays and shown to be endotoxin
negative. The anti-human CD18, clone 7E4 (Immunotech,
Marseilles, France), was used in ADCC inhibition assays. To
quantify the MAb binding to Ep-CAM using flow cytometry, the
Fab fragments of the chimeric 323/A3 and 17-1A MAbs, directly
labelled with FLUOS (Boehringer Mannheim, Mannheim,
Germany), were used.
Cell lines
The SV40 immortalized human breast epithelial cell line HBL
100, clone HCA (kindly provided by Dr J Hilkens, NKI,
Amsterdam, The Netherlands), the mouse mammary carcinoma
cell line L153S (Litvinov et al, 1994a) and the transfectants HCA-
M and C1.5 and C1.13 were all cultured in Dulbecco's modified
Eagle medium (DMEM) supplemented with 10% heat-inactivated
fetal calf serum (Gibco-BRL, Paisley, UK). 50 gg ml-' strepto-
mycin and 50 tg ml-' penicillin at 37°C and 5% carbon dioxide.
Generation of Ep-CAM transfected cells
For the generation of Ep-CAM-expressing murine L153 cells the
SmaI/BglII fragment ofthe GA733-2 Ep-CAM cDNA (Szala et al,
1990) was subcloned into the pJSQ eukaryotic expression vector
(Morgenstern and Land, 1990) under the transcriptional control of
the dexamethasone inducible promotor of the MMTV LTR. Two
clones, C1.5 and C1.13, were used for this study. For the genera-
tion of Ep-CAM-expressing human HCA cells, the Ep-CAM
cDNA was cloned into the pMEP4 expression vector (Invitrogen,
Leek, The Netherlands), under the control of the inducible
metallothionein promoter; the Ep-CAM-transfected HCA cell line
is referred to as HCA-M. Transfection of both human and murine
cells was performed using DOTAP (Boehringer Mannheim) as
previously described (Litvinov et al, 1994a). After selection with
the appropriate antibiotic, Ep-CAM expression of selected clones
was identified using FACS analysis with MAb 323/A3. Induction
of Ep-CAM expression in HCA-M or C1.5 and C1.13 cells was
obtained by 16-h cultivation of the cells in the presence of 10-6 M
dexamethasone or 1-100gM zinc sulphate respectively.
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Figure 1 Expression of Ep-CAM in clones C1.13 and C1.5 obtained by
transfection of Li 53 murine cells (A) and in transfected HCA, human
mammary cells (B). Murine cells were transfected using a vector with the
MMTV promotor. Therefore, expression of Ep-CAM could be induced by
adding dexamethasone (D) up to 10- M. The HCA cells contain an episomal
vector with Ep-CAM cDNA under the control of the metallothionein promoter,
which can be induced by adding Zn2+ ions at various concentrations. Data
presented are mean fluorescence numbers obtained with Ep-CAM detection
using directly FITC-labelled Fab fragments of MAbs cl7-1A (C) or 323A3
(U). The Fab fragments were added in an excess, and their binding reflects
the best estimate of Ep-CAM level at the cell surface
Antibody-binding assay
To detect the binding of the chimeric MAbs 17-1A and 323/A3 to
Ep-CAM present at the surface of the tumour cells, Ix106 cells
were incubated in 200 ,ul of PBS with directly fluorescein isothio-
cyanate (FITC)-labelled chimeric 17-lA, 323/A3 or SF25 MAbs
at 100 .tg ml-' for I h at 4°C. The chimeric MAb SF25 IgGI
(Takahashi et al, 1995) was used as a non-binding negative control
in these assays. After washing three times with PBS at 4°C, the
cells were resuspended in 300 ,ul ofcold PBS containing 1 gg ml
propidium iodide to discriminate between viable and dead cells in
flow cytometry. Immediately after staining 10 000 viable cells
from each sample were examined in flow cytometry for the
amount of MAb bound. The results are presented as the mean
fluorescence after subtraction of the background staining with
chimeric MAb SF25.
Antibody-dependent cellular cytotoxicity
One large batch of human peripheral blood lymphocytes (PBLs)
from a single healthy donor was isolated by Ficoll-Isopaque
centrifugation and cryopreserved until used as effector cells. The
day before the ADCC assay, a vial of human PBLs was thawed
and the PBLs were activated by overnight culture in the presence
of 150 IU ml-' IL-2 (Eurocetus, Amsterdam, The Netherlands).
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All ADCC experiments described in this study were performed
with PBLs from the same batch. Tumour cells (1x106) were
detached and washed twice before labelling for 90 min with
100 gCi 51Cr in PBS (Amersham, Buckinghamshire, UK) at 37°C
and 5% carbon dioxide. Cells were washed twice with 2 ml of
medium and resuspended at a concentration of Ix104 cells ml. A
50-ml aliquot of medium containing MAb was added to 100 ml of
tumour cell suspension (1000 cells per well) in 96-well round-
bottom microtitre plates (Greiner, Langenthal, Switzerland), and
subsequently the effector cells were added in 100gl at various
effector-target cell (E/T) ratios. After 4 h incubation at 37°C and
5% carbon dioxide, 100 gl of supematant was removed and
counted for the presence of 51Cr (ER, experimental release) in an
LKB gamma-counter. The maximum release (MR) was obtained
by adding 100 tl of 1% Triton X-100 to 100 tl of labelled cells
plus 50 ,ul of medium. Background release (BR) was measured by
incubating 100gl of labelled cells with 150,l of medium.
Specific release (SR) was calculated as follows: SR = (ER - BR /
MR - BR) x 100%. All assays were performed in triplicate. In
experiments on the role of the accessory molecules, the effector
cells were preincubated before the experiment with the MAb
against CD18 (10 tg of MAb per 107 PBLs in 1 ml of DMEM for
30 min at 20°C). After the incubation, the volume of the medium
was adjusted to 20 ml, and the effector suspension was added to
the target cells as described above. The final concentration ofanti-
CD18 MAb during the cytotoxicity assay was 0.2 gg ml'.
RESULTS
Inducible expression of Ep-CAM in transfected cells
Two cell clones, C1.5 and C1.13, obtained by transfection of
L153S murine carcinoma cells with Ep-CAM cDNA under the
control ofthe inducible MMTV promotor were tested for Ep-CAM
expression. The expression of Ep-CAM at the surface of cells,
without and 24 h after induction with 106 M dexamethasone, was
determined by FACScan analysis (Figure IA). Both the basic and
the induced levels of Ep-CAM expression differed significantly
between clones C1.5 and C1.13. Comparison of the binding of
chimeric 17-lA and 323/A3 MAbs to the Ep-CAM transfected
murine cells, as was determined by flow cytometry using FITC-
labelled Fab fragments, showed that at equal concentrations (the
data is shown for 10 ,ug ml'), MAb 323/A3 bound approximately
tenfold better than MAb 17-1A to the same target cells.
Ep-CAM expression could also be up-regulated in HCA-M
cells, derived from the human HCA cell line by transfection ofEp-
CAM cDNA under the control of the inducible metallothionein
promoter. As analysed using flow cytometry, treatment ofHCA-M
cells with 100 jtM zinc sulphate elevated the Ep-CAM expression
approximately sixfold over uninduced Ep-CAM expression levels.
Induction of Ep-CAM expression did not lead to a linearly
increased binding of c17-4A and c323/A3 MAbs (Figure IB).
Nevertheless, at the same antibody concentration, MAb 323/A3
bound approximately tenfold better to the HCA-M cells than
MAb 17-lA.
ADCC is determined by antigen expression levels and
antibody affinity
To examine the impact ofantigen expression levels on the efficacy
of ADCC, the uninduced and dexamethasone-induced murine
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Figure 2 Titration for antibody binding (solid symbols) and ADCC (open
symbols) of chimeric MAbs 17-1A (A) and 323/A3 (B) on dexamethasone
induced (A, A) and uninduced (El, *) murine C1.5 cells. MAb binding as
determined by FACScan analysis is presented as mean fluorescence on the
right y-axis. ADCC assays were carried out at an effector-target ratio of 50:1
in parallel with the MAb-binding assay. This figure represents three
independently performed MAb titration experiments
C1.5 and C1.13 Ep-CAM-transfected cell lines, respectively, were
used in parallel for FACscan analysis and ADCC assays (Figure 2)
with activated human PBLs and chimeric c323/A3 or c17-lA
MAbs. The treatment of target cells with dexamethasone did not
increase the susceptibility of cells to ADCC, as was tested using a
control L153S transfectant containing Ep-CAM cDNA in the
pJ3Q expression vector under the control ofthe constitutive SV40
promotor (data not shown). No lysis was observed for C1.5 and
C1.13 cells (data not shown) by activated human PBLs in the
absence ofADCC-mediating antibodies.
In the presence of antibody, the cells with induced Ep-CAM
expression were killed better in ADCC with MAbs c17-lA (Figure
2A) and c323/A3 (Figure 2B) than their uninduced counterparts.
Moreover, C1.5 cells, which express higher Ep-CAM levels than
C1.13 cells both before and after induction of Ep-CAM (Figure
IA), were killed more efficiently with c323/A3 and c17-1A than
C1.13 cells (data not shown). With c17-lA, despite demonstrable
binding of the antibody to the induced murine cells at 10 gg ml',
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Figure 3 Representative graph of four kinetic ADCC experiments mediated
with either 10 jig ml-' chimeric MAb 17-1A (A) or 323/A3 (B) in the presence
of human PBL at an effector-target ratio 50:1 on human HCA cells (+) and
derived Ep-CAM transfectants HCA-M cells, either uninduced HCA-M 0 (0)
or induced with 10 (A) or 100 (M) JIM zinc sulphate respectively. The
percentage-specific 5Cr release from the cells was determined after 2, 3 and
5 h of incubation of human target and effector cells at 37°C and 5% carbon
dioxide. Results of parallel experiments on binding of chimeric 17-lA and
323/A3 MAbs to these cells are presented in Figure 1
ADCC was only obtained at MAb concentrations above tg
ml- (Figure 2A). The binding ofMAb c17-lA to dexamethasone-
induced C1.5 cells was similar to the binding of MAb c323/A3 to
uninduced Cl.5 cells (Figure 2B), resulting in similar average
numbers of MAb Fc-tails from both MAbs available for Fc-
receptor binding. Nevertheless, ADCC in these two instances
A
50
L- a)
a,
C)
a-)
.)_
C)
B
when mediated by MAb c323/A3 was higher than lysis mediated
by MAb c17-lA. These experiments, with the data presented in
Figure 2A and B, show that cell lysis by ADCC is dependent on
the total amount of antibody bound to the cells but also on anti-
body affinity.
ADCC with murine targets was performed using human effector
cells. In a combination of effector and target, one may expect a
decrease, if not a complete exclusion (Mentzer et al, 1986;
Johnston et al, 1990), of the adhesive interactions between the
effector and target cell. The impact of MAb affinity and antigen
expression levels on ADCC, in the presence of accessory adhesion
molecules on the target cells and the matching counterparts on the
effector cells, was studied using human PBLs against transfected
human HCA-M target cells with inducible Ep-CAM expression.
ADCC assays (Figure 3) and FACscan analysis for Ep-CAM
expression levels and MAb binding (Figure IB) were carried out
in parallel. Again, in all experiments, MAb c323/A3 consistently
mediated higher lysis than MAb 17-1A (compare the lysis levels at
the 4-h time point in Figure 3).
ADCC kinetics and MAb affinity
The kinetics of the ADCC reaction was investigated using human
PBLs and human HCA-M target cells with different Ep-CAM
expression levels. Specific lysis (Figure 3) with MAb c17-lA was
clearly related to the amount ofMAb bound to the target cells. For
MAb c323/A3 this was less pronounced; the elevation of antigen
expression above the baseline expression seen in the HCA-M cells
without induction, led to only minor increases in ADCC (Figure
3). With mAb c17-lA on induced HCA-M cells, ADCC almost
reached a lysis plateau level after 1 h ofincubation. Although lysis
of HCA-M cells after 1 h of incubation with MAb c323/A3 was
higher than with mAb c17-1A, no lysis plateau values were
evident even after 5 h of incubation. The data from these experi-
ments showed that for human target cells the kinetics of ADCC
were determined by the level of antigen expression and strongly
influenced by MAb affinity.
Influence of the adhesive effector-target interactions
on ADCC in relation to MAb affinity
Using human effectors and HCA transfectants with Ep-CAM
induced at different levels, we investigated to what extent the addi-
tional contact adhesions between effector and target cell affect
C
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Figure 4 Effect of anti-CD 18 MAb on ADCC. Targets: HCA-M cells with Ep-CAM induced by 10 lM (A, B) or by 100 tM zinc sulphate (C). Antibodies used:
1 ig of chimeric 17-1A or 323/A3 (A) or chimeric 17-1A in designated concentrations (B, C). *, lysis in the absence of anti-CD18; O, ADCC in the presence of
0.2 ,ig ml' of anti-CD18 MAb. Note that the negative effect of anti-CD18 MAb on ADCC (3), especially when mediated by 17-1A, can be compensated by an
increase in either the concentration of MAb or the antigen density on the target cells
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ADCC. As was tested in flow cytometry, neither ICAM-1 nor LFA-
3 expression on HCA and HCA-M cells was substantially affected
by the Zn2+ cations in medium or by Ep-CAM expression (not
shown). As shown in Figure 4A, at a given concentration of the
MAb, ADCC mediated by a high-affinity MAb c323/A3 was not
sensitive to the blocking of the effector's accessory molecules with
an anti-CD18 MAb. For the low-affinity MAb c17-lA, the ADCC
was blocked at the given conditions; however, by either increasing
the MAb concentration 100 times (Figures 4B and 4C) or by
inducing the antigen expression on the target cells (Figure 4C)
MAb 17-1A mediated lysis of the targets even in the presence of
the anti-CD 18 MAb. For the high-affinity MAb c323/A3 the obser-
vations were similar, but at more than 100 times lower concentra-
tions of the MAb (data not shown). These results suggest that,
except for MAb affinity and antigen density, the efficacy of ADCC
also depends on the presence of accessory molecules. However, the
absence of additional effector-target adhesive interactions may be
compensated by increasing the number or strength of the MAb-
mediated interactions between effector and target cells.
DISCUSSION
To be effective, immunotherapy of tumours requires complete
elimination of tumour cells. At present, it is not known to what
extent heterogeneous antigen expression by individual tumour
cells represents a problem in therapy with MAbs, but it is quite
likely that tumour cells with low levels of target antigen, similarly
to the antigen-negative cells, may escape MAb-mediated immuno-
therapy (Fleuren et al, 1995). As ADCC is considered to be the
major mechanism of MAb action in therapy (Adams et al, 1984),
we performed this study on the importance ofantigen density and
MAb affinity for ADCC efficacy. In contrast to other studies in
this field (Capone et al, 1984; Hagan et al, 1986; Fogler et al,
1988), our approach is the first one that allows the study of the
effect of antigen density on ADCC on established tumour cell
clones with inducible antigen expression.
The results showed that the antibody affinity was of major
importance for effective tumour cell binding and lysis through
ADCC as the high-affinity MAb 323/A3, at equal MAb concentra-
tions, bound better to tumour cells with the same antigen expres-
sion than the low-affinity MAb 17-1A. Even at comparable levels
ofbinding to the targets the 323/A3 MAb was more efficient than
17-lA. In addition, it was found that the efficacy of ADCC with
both MAbs 17-lA and 323/A3 was dependent on Ep-CAM
expression levels both in murine and in human model cell lines.
Cells with relatively higher Ep-CAM levels were lysed more effi-
ciently than cells with lower Ep-CAM expression levels.
As a consequence, MAb 323/A3 consistently mediated higher
ADCC than MAb 17-1A against the same tumour cells. This is in
agreement with our previous results on Ep-CAM expressing LS
180 human colorectal carcinoma cells (Velders et al, 1995).
Moreover, not only in vitro, but most importantly also in vivo,
MAb 323/A3 mediated killing of tumour cells that were not killed
by MAb 17-IA (Velders et al, 1996). In agreement with Herlyn et
al. (1985), our results, as presented in Figure 2, show that ADCC
requires a minimal threshold number of antibodies bound to the
target cells and that this threshold is dependent on antibody affinity,
i.e. higher for a low-affinity MAb such as 17-1A than for a high-
affinity MAb 323/A3. Against murine tumour cells with low Ep-
CAM expression levels (see Figure 2) chimeric MAb 17-IA was
unable to elicit a cytotoxic response at MAb concentrations below
50,tg ml-', whereas MAb 323/A3 at 1 gg ml-' effectively killed
these low Ep-CAM-expressing cells. Apparently not only the
number ofengaged FcRy receptors on the effector cell is important,
but also the strength of the interconnections to the target antigen
affects the activation signal to the effectors (Velders et al, 1996)
The requirement of accessory adhesions between effector and
target for ADCC is not very clear, however the scope of the publi-
cations on the subject suggests their importance (Liesveld et al,
1991; Webb et al, 1991; Edwards et al, 1992; Kushner and
Cheung, 1992). Our results suggest that the importance of addi-
tional adhesive interactions between effector and target cells in
ADCC is influenced by the overall number and strength of anti-
body-mediated interconnections between the two cells. As both
antibodies used, 17-IA and 323/A3, have identical Fc fragments
[owing to their chimerization using the same genes for the
constant Ig chains (Sun et al, 1987; Velders et al, 1994)], it is the
affinity of the antibody to the target antigen or the three-dimen-
sional orientation of Fc tails that is of importance. From the results
presented in Figure 4 we conclude that high MAb affinity, or a
large number of antibody-antigen interconnections between
effector and target cells, may well compensate the reducing effect
on ADCC of the suppressed accessory interactions.
Knowledge of the kinetics of the ADCC reaction with different
MAbs could also help when choosing MAbs for immunotherapy.
We provided evidence that, against the same HCA-M cells, the
high-affinity MAb 323/A3 not only mediated higher lysis, but also
continued to mediate cell lysis for an extended period, whereas an
extended incubation with MAb 17-1A had no additional effect.
The observed lack of plateau values in ADCC in a 5 h assay
against human target cells with MAb 323/A3, and the overall
higher lysis levels obtained, indicates that MAb 323/A3 can
mediate the killing of Ep-CAM-expressing tumour cells that
cannot be killed by MAb 17-lA, which is in agreement with our
previous in vivo results (Velders et al, 1996). It seems plausible
that only the cells with the highest levels of Ep-CAM expression
were killed by the 17-1A MAb, and that cells with lower levels of
expression were not lysed. However, such cells could be lysed by
the 323/A3 MAb. Based on our previous in vivo results and the
data presented here, we conclude that the high-affinity 323/A3
MAb can eliminate substantially more cells from a heterogeneous
tumour cell population than the low-affinity MAb 17-1A. It's also
possible that low Ep-CAM-expressing tumour cells in patients
may be more effectively eradicated using the high-affinity MAb
323/A3 instead ofMAb 17-1A.
ABBREVIATIONS
ADCC, antibody dependent cellular cytotoxicity; Ep-CAM,
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